What is the difference? Moxidectin and Milbemycin oxime

There are two ways to prevent Angiostrongylosis:

1Moxidectin

Products containing moxidectin e.g. Advocate® prevent angiostrongylosis and patent infecti on with Angiostrongylus vasorum.

2Milbemycin oxime

Products containing milbemycin oxime prevent angiostrongylosis by reducing the level of infection with immature adult (L5) and adult stages of Angiostrongylus vasorum.

Examples of separate studies accepted by the regulator to justify the SPC wording (not direct comparison study); study designs differ but both conform to required VICH Good Clinical Standards guidelines. Refer to individual studies for full details.

Advocate® Prevention Study1

Single challenge model – each dog given 200 L3 larvae in one go. Model successful in establishing infection in control group (8 dogs) with average of 99 worms. Two treatment groups (8 dogs each) received a single dose of Advocate®, at minimum licensed dose, 4 days post infection or 32 days post infection. Study duration of 56-59 days determined by time taken to confirm L1 larval shedding in all control dogs before study endpoint and assessment of worm numbers in all groups.

NexGard Spectra® Prevention Study2

‘Trickle’ challenge model – each dog given between 32 & 41 L3 larvae 7 times (at 2 week intervals) meaning ~260 L3 larvae in total. Model successful in establishing infection in the control group (10 dogs) with average of 66 worms. Treatment group (10 dogs) received NexGard Spectra®, at ~minimum licensed dose, 7 days post first infection and then repeated every 4 weeks on 4 occasions. Study duration of 97-99 days resulted in L1 larval shedding in all control dogs before study endpoint and assessment of worm numbers in all groups.

Studies also assessed L1 larval shedding: compared to untreated controls excretion in NexGard Spectra® treated dogs was reduced by 99.9% (with 2 of 10 dogs shedding a low number of larvae); with Advocate® there was a 100% reduction with no L1 larvae being shed in any of the treated dogs.

What is Lungworm (Angiostrongylus vasorum)?

What is the extent of the problem in the UK & Ireland?

Lungworm prevention with Advocate

What do the experts say?

References

  1. Schnyder M, et al., Vet Parasitol. 2009;166(3-4):326-332.
  2. Lebon et al. Parasites & Vectors (2016) 9:485.
  3. Taylor et al. Parasitology (2015) 142(9):1190-5.
  4. Map data from multiple sources including laboratory results, publications, and vet case reports, see the Lungworm website for more information.
  5. McCarthy et al., Parasitology (2016), 143, 588–593.

Note: X-ray image in banner is for artistic purposes only; not intended to show clinical information or differences. Products containing moxidectin & milbemycin oxime are licensed to prevent angiostrongylosis; see SPCs/datasheets for details 
of how this is achieved in different ways.

NexGard Spectra® is a registered trademark of Merial.